Predicted coverage by 4CMenB vaccine against invasive meningococcal disease cases in the Netherlands

被引:13
|
作者
Freudenburg-de Graaf, W. [1 ,2 ]
Knol, M. J. [3 ]
van der Ende, A. [1 ,2 ]
机构
[1] Univ Amsterdam, Dept Med Microbiol & Infect Prevent, Amsterdam UMC, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
[2] Netherlands Reference Lab Bacterial Meningitis, Amsterdam, Netherlands
[3] Natl Inst Publ Hlth & Environm, Ctr Infect Dis Control Netherlands, Bilthoven, Netherlands
基金
英国惠康基金;
关键词
Neisseria meningitidis; 4CMenB vaccine; Whole-genome sequencing; gMATS; B VACCINE; BACTERICIDAL ANTIBODIES; PERSISTENCE; AGE; IMMUNOGENICITY; IMMUNIZATION; ADOLESCENTS; INFANTS; STRAIN;
D O I
10.1016/j.vaccine.2020.10.008
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Neisseria meningitidis serogroup B is a major cause of invasive meningococcal disease in Europe. In the absence of a conjugate serogroup B vaccine, a subcapsular 4CMenB vaccine was developed. Data on 4CMenB vaccine efficacy is still limited. Recently, genomic MATS (Meningococcal Antigen Typing System) was developed as a tool to predict strain coverage, using vaccine antigens sequence data. We characterized all invasive meningococcal isolates received by the Netherlands Reference Laboratory for Bacterial Meningitis (NRLBM) in two epidemiological years 2017-2019 using whole-genome sequencing and determined serogroup, clonal complex (cc) and estimated 4CMenB vaccine coverage by gMATS. Of 396 cases of invasive meningococcal disease, corresponding to an incidence of 1.22 cases/10(5) inhabitants, 180 (45%) were serogroup W, 155 (39%) serogroup B, 46 (12%) serogroup Y, 10 (3%) serogroup C, 2 non-groupable (0.5%) and 3 (0.7%) unknown. The incidence was the highest among 0-4 years olds (4 cases/10(5) inhabitants), and 57/72 (79%) of these cases were serogroup B. Serogroup W predominated among persons 45 years of age or older with 110/187 (59%) cases. Serogroup B isolates comprised 11 different clonal complexes, with 103/122 (84%) isolates belonging to 4 clonal complexes: cc32, cc41/44, cc269 and cc213. In contrast, serogroup W isolates were genetically similar with 95% belonging to ccl 1. Of 122 serogroup B isolates, 89 (73%; 95% CI: 64-80%) were estimated to be covered by 4CMenB and the degree of coverage varied largely by clonal complex and age. Among the 0-4 year olds, 25 of 43 (58%; 95% CI: 43-72%) MenB isolates were estimated to be covered. Since the coverage of the 4CMenB vaccine is dependent on circulating clonal complexes, our findings emphasize the need for surveillance of circulating meningococcal strains. In addition, estimation of age specific coverage is relevant to determine the right target age group for vaccination. (C) 2020 The Authors. Published by Elsevier Ltd.
引用
收藏
页码:7850 / 7857
页数:8
相关论文
共 50 条
  • [1] Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Portugal
    Simoes, Maria Joao
    Bettencourt, Celia
    De Paola, Rosita
    Giuliani, Maria
    Pizza, Mariagrazia
    Moschioni, Monica
    Machado, Jorge
    PLOS ONE, 2017, 12 (05):
  • [2] Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment
    Vogel, Ulrich
    Taha, Muhamed-Kheir
    Vazquez, Julio A.
    Findlow, Jamie
    Claus, Heike
    Stefanelli, Paola
    Caugant, Dominique A.
    Kriz, Paula
    Abad, Raquel
    Bambini, Stefania
    Carannante, Anna
    Deghmane, Ala Eddine
    Fazio, Cecilia
    Frosch, Matthias
    Frosi, Giacomo
    Gilchrist, Stefanie
    Giuliani, Marzia M.
    Hong, Eva
    Ledroit, Morgan
    Lovaglio, Pietro G.
    Lucidarme, Jay
    Musilek, Martin
    Muzzi, Alessandro
    Oksnes, Jan
    Rigat, Fabio
    Orlandi, Luca
    Stella, Maria
    Thompson, Danielle
    Pizza, Mariagrazia
    Rappuoli, Rino
    Serruto, Davide
    Comanducci, Maurizio
    Boccadifuoco, Giuseppe
    Donnelly, John J.
    Medini, Duccio
    Borrow, Ray
    LANCET INFECTIOUS DISEASES, 2013, 13 (05): : 416 - 425
  • [3] High predicted strain coverage by the multicomponent meningococcal serogroup B vaccine (4CMenB) in Poland
    Wasko, Izabela
    Hong, Eva
    De Paola, Rosita
    Stella, Maria
    Moschioni, Monica
    Taha, Muhamed-Kheir
    Skoczynska, Anna
    VACCINE, 2016, 34 (04) : 510 - 515
  • [4] Meningococcal carriage: the dilemma of 4CMenB vaccine
    Taha, Muhamed-Kheir
    Deghmane, Ala-Eddine
    LANCET, 2014, 384 (9960): : 2088 - 2090
  • [5] Genomic Characterization of Invasive Meningococcal Serogroup B Isolates and Estimation of 4CMenB Vaccine Coverage in Finland
    Bodini, Margherita
    Brozzi, Alessandro
    Giuliani, Maria
    Nohynek, Hanna
    Vainio, Anni
    Kuusi, Markku
    De Paola, Rosita
    Pizza, Mariagrazia
    Medini, Duccio
    Toropainen, Maija
    Serino, Laura
    Muzzi, Alessandro
    MSPHERE, 2020, 5 (05):
  • [6] Diversity of greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine
    Georgina Tzanakaki
    Eva Hong
    Konstatinos Kesanopoulos
    Athanasia Xirogianni
    Stefania Bambini
    Luca Orlandi
    Maurizio Comanducci
    Alessandro Muzzi
    Muhamed-Kheir Taha
    BMC Microbiology, 14
  • [7] Diversity of greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine
    Tzanakaki, Georgina
    Hong, Eva
    Kesanopoulos, Konstatinos
    Xirogianni, Athanasia
    Bambini, Stefania
    Orlandi, Luca
    Comanducci, Maurizio
    Muzzi, Alessandro
    Taha, Muhamed-Kheir
    BMC MICROBIOLOGY, 2014, 14
  • [8] Culture-Confirmed Invasive Meningococcal Disease in Canada, 2010 to 2014: Characterization of Serogroup B Neisseria meningitidis Strains and Their Predicted Coverage by the 4CMenB Vaccine
    Tsang, Raymond S. W.
    Law, Dennis K. S.
    De Paola, Rosita
    Giuliani, Maria
    Stella, Maria
    Zhou, Jianwei
    Deng, Saul
    Boccadifuoco, Giuseppe
    Giuliani, Marzia Monica
    Serino, Laura
    MSPHERE, 2020, 5 (02)
  • [9] Evaluating the effectiveness of the 4CMenB vaccine against invasive meningococcal disease and gonorrhoea in an infant, child and adolescent program: protocol
    Marshall, Helen S.
    Andraweera, Prabha H.
    Wang, Bing
    McMillan, Mark
    Koehler, Ann P.
    Lally, Noel
    Almond, Sara
    Denehy, Emma
    A'Houre, Michele
    Giles, Lynne C.
    Flood, Louise
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (05) : 1450 - 1454
  • [10] Meningococcal Group B Vaccine (4CMenB) in Children
    Lopez-Lacort, Monica
    Munoz-Quiles, Cintia
    Orrico-Sanchez, Alejandro
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (22): : 2109 - 2109